Study guide
10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics
Key Takeaways Explain This Topic AI
Immunohistochemistry (IHC) uses antibodies to detect proteins in tissue, such as ER, PR, HER2, Ki-67, PD-L1, mismatch repair proteins, and lineage markers like TTF-1 or CDX2.
Fluorescence in situ hybridization (FISH) uses labeled DNA probes to count gene copies or detect rearrangements, such as HER2 (ERBB2) amplification or ALK rearrangement.
PCR amplifies DNA; RT-PCR first converts RNA into DNA, so it detects gene expression or fusion transcripts such as BCR::ABL1; next-generation sequencing tests many genes at once.
Flow cytometry measures cell-surface markers on individual cells (immunophenotyping) and is central to diagnosing leukemias and lymphomas; cytogenetics (karyotype) shows chromosomal changes.
For hematopoietic neoplasms, a positive histology plus positive immunophenotyping and/or genetic testing is Diagnostic Confirmation code 3; for solid tumors, biomarkers are recorded in SSDIs but are not used to decide multiple primaries.
Last updated: September 2026
Why lab methods are tested
The ODS outline lists "specialty lab testing methods (e.g., RT-PCR, FISH)." Registrars do not perform the tests, but they must recognize what a report means. For example, "HER2 IHC 2+, reflex FISH ratio 2.4" means HER2-positive. "BCR::ABL1 detected by RT-PCR" confirms CML. They must also know which registry item the result belongs in.
- Tissue-based protein and DNA tests
- Immunohistochemistry (IHC)
How it works: antibodies tagged with a colored label bind to specific proteins in tissue sections, and the pathologist scores the percentage and intensity of stained cells.
Uses:
Breast: ER and PR (reported as percent of nuclei stained; 1% or more is positive, and 1–10% is "low positive" under ASCO/CAP guidance), HER2 (scored 0, 1+, 2+ or 3+), Ki-67 proliferation index.
Lineage and site of origin: TTF-1 (lung and thyroid), CDX2 and CK20 (colorectal), CK7, PAX8 (kidney and Müllerian), GATA3 (breast and urothelial), PSA and NKX3.1 (prostate), S100 and SOX10 (melanoma), chromogranin and synaptophysin (neuroendocrine).
Mismatch repair (MMR) proteins MLH1, PMS2, MSH2 and MSH6: loss of staining means deficient MMR (dMMR).
PD-L1 (tumor proportion score or combined positive score) to predict response to immunotherapy.
In situ hybridization (ISH), including FISH
How it works: labeled DNA probes bind matching DNA sequences in place in cells. FISH uses fluorescent probes; CISH and SISH use chromogenic or silver probes that can be read with a regular microscope.
Uses: gene amplification , such as HER2 (ERBB2) in breast and gastric cancer, which is usually reported as a HER2/CEP17 ratio plus the average HER2 copy number. Gene rearrangements such as ALK and ROS1 in lung cancer, and MYC, BCL2 and BCL6 in lymphoma. Deletions such as 1p/19q codeletion in oligodendroglioma, and del(17p) in CLL and myeloma.
Typical workflow: HER2 IHC 2+ (equivocal) leads to reflex ISH, and the ISH result decides the final HER2 status. IHC 3+ is positive, and 0 or 1+ is negative. HER2-low (1+, or 2+ with negative ISH) is a clinical category used for newer therapies.
- Nucleic acid amplification and sequencing
- PCR and RT-PCR
Polymerase chain reaction (PCR) makes millions of copies of a targeted DNA sequence, so small mutations can be detected (for example, KRAS codon 12 or 13, BRAF V600E, EGFR exon 19 deletion or L858R). Quantitative (real-time) PCR also measures how much target is present.
Reverse transcription PCR (RT-PCR) first converts RNA into complementary DNA with reverse transcriptase, then amplifies it. It detects gene expression or fusion transcripts . Examples:
BCR::ABL1 transcripts confirm CML (with the t(9;22) Philadelphia chromosome), and quantitative RT-PCR monitors treatment response.
The 21-gene recurrence score (Oncotype DX) measures RNA expression by RT-PCR to estimate breast cancer recurrence risk. AJCC uses it in prognostic staging.
PML::RARA in acute promyelocytic leukemia.
MSI testing by PCR compares microsatellite lengths in tumor and normal tissue: MSI-H (high), MSI-L (low) or MSS (stable).
Next-generation sequencing (NGS)
NGS sequences many genes, or whole exomes or genomes, at once. Panels detect point mutations, insertions and deletions, copy-number changes, fusions (with RNA-based NGS), tumor mutational burden (TMB) and MSI.
Uses: lung cancer driver panels (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, NTRK), colorectal (KRAS, NRAS, BRAF, MSI), and hereditary cancer germline panels (BRCA1/2, Lynch genes).
Germline vs. somatic: germline testing of blood or saliva identifies inherited risk. Somatic testing of the tumor identifies acquired changes that guide treatment.
Liquid biopsy
Circulating tumor DNA (ctDNA) in blood can reveal targetable mutations or residual disease. It is a biomarker test, not tissue confirmation for Diagnostic Confirmation.
Gene-expression profiling
Multigene assays estimate prognosis. Examples are the 21-gene recurrence score (RT-PCR) and the 70-gene signature (MammaPrint, microarray) in breast cancer, and genomic classifiers in prostate cancer. These appear in the breast multigene signature SSDIs.
Cell-based and chromosome tests (mainly hematologic)
Method What it detects Examples
Flow cytometry Surface and intracellular markers on thousands of single cells ( immunophenotyping ), plus light chain restriction (clonality) B-cell markers (CD19, CD20), T-cell markers (CD3), blast markers (CD34, CD117); lineage for AML vs. ALL; CLL phenotype (CD5+, CD23+)
Conventional cytogenetics (karyotype) Whole-chromosome number and structural changes in dividing cells t(9;22) in CML; t(15;17) in APL; complex karyotype in MDS/AML
Serum and urine protein electrophoresis, immunofixation, free light chains Monoclonal (M) protein Plasma cell myeloma, MGUS (MGUS is not reportable)
Where the results go in the registry
Result Registry item or rule
ER, PR, HER2, multigene score (breast); MSI, KRAS, CEA (colorectal); PSA and Gleason (prostate); Breslow and ulceration (melanoma); and others Site-Specific Data Items (SSDIs) , coded with NAACCR SSDI Manual codes (Section 10.4)
Histology confirmed plus immunophenotyping and/or genetics for a heme neoplasm Diagnostic Confirmation 3 (hematopoietic and lymphoid only)
A heme disease whose definitive diagnosis requires a specific test Heme DB "Definitive Diagnostic Methods" for that histology
Biomarkers in solid tumors Recorded in SSDIs. The Solid Tumor Rules say not to code multiple primaries or histology from biomarkers.
Germline mutation found in a patient with no cancer Not reportable : genetic findings without evidence of disease indicate risk only (STORE)
Quick contrasts
IHC measures protein; FISH looks at DNA copies or rearrangements; RT-PCR detects RNA.
Flow cytometry works on cells in suspension (blood, marrow, fluid); IHC works on fixed tissue sections.
MMR IHC looks for missing proteins, MSI PCR or NGS looks for the DNA effect, and both identify the same biology (dMMR/MSI-H).